Human IGFBP-1 ELISA kit
- Known as:
- Human IGFBP-1 Enzyme-linked immunosorbent assay test reagent
- Catalog number:
- lf-ek50097
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Abfrontier
- Gene target:
- Human IGFBP-1 ELISA kit
Related genes to: Human IGFBP-1 ELISA kit
- Gene:
- CCN1 NIH gene
- Name:
- cellular communication network factor 1
- Previous symbol:
- IGFBP10, CYR61
- Synonyms:
- GIG1
- Chromosome:
- 1p22.3
- Locus Type:
- gene with protein product
- Date approved:
- 1998-03-02
- Date modifiied:
- 2018-10-11
- Gene:
- IGFBP1 NIH gene
- Name:
- insulin like growth factor binding protein 1
- Previous symbol:
- IBP1
- Synonyms:
- IGF-BP25, AFBP, hIGFBP-1, PP12
- Chromosome:
- 7p12.3
- Locus Type:
- gene with protein product
- Date approved:
- 1988-11-30
- Date modifiied:
- 2015-11-12
Related products to: Human IGFBP-1 ELISA kit
Related articles to: Human IGFBP-1 ELISA kit
- Metabolic dysfunction associated steatotic liver disease (MASLD) is the most prevalent liver disease, yet accurate early detection remains challenging. A particular diagnostic obstacle is distinguishing MASLD from metabolic dysfunction and alcohol-related liver disease (MetALD), currently defined using clinically informed moderate alcohol consumption thresholds without biological validation. This study aimed to identify and externally validate plasma proteomic signatures associated with MASLD and assess whether proteomic profiles support a molecular distinction between MASLD and MetALD as currently defined. - Source: PubMed
Jakhar NiharikaSeibel TobiasMironova MariaMeeßen CorinnaClusmann JanChen YazhouRaju Thriveni BKoop Paul-HenryPearce Juliette ECosta Ivan GStiehl ThomasSchuppert AndreasSchneider Kai MarkusRotman YaronSchneider Carolin V - A higher ratio of IGF-1:IGF binding protein 1 (IGFBP1) was associated with improved prognosis in the CHAARTED trial of docetaxel in participants with metastatic hormone-sensitive prostate cancer (mHSPC). The ENZAMET trial demonstrated the survival benefit of adding enzalutamide to androgen deprivation therapy (ADT) in mHSPC, and included participants who also received docetaxel as standard of care. The aim of this study was to validate the association between levels of circulating IGF-1 and IGFBP1 and survival of ENZAMET participants. - Source: PubMed
Publication date: 2026/09/27
Cilento Michael ALin Hui-MingYeung NicoleKim Rachel M NPortman NeilStockler Martin RMartin Andrew JSubhash VinodYip SoniaButler Lisa MMarschner Ian CMeikle Peter JAzad Arun ADavis Ian DHorvath Lisa GSweeney Christopher J - In eutherians, Insulin-like Growth Factor-I (IGF-I) and IGF-II exert insulin-like activity by interacting with type-I receptor. IGF bioavailability is finely regulated by six IGF-Binding Proteins (IGFBPs), IGFBP-1 to -6, which bind IGF-I and -II with high affinity but not insulin. Moreover, the Pregnancy-Asssociated Plasma Protein-A protease in able to specifically degrade IGFB-2, -4, -5. In the present work, we were interested in the evolution of this regulation of bioavailability in vertebrates, in particular in the question of the different nodes of appearance of IGFs, IGFBPs and PAPP-A in the tree of life. We confirmed that insulin-like/IGF peptides and their receptors appeared in non-vertebrate species, whereas IGFBPs first appeared in the vertebrate ancestor. More precisely, the first IGFBP that appeared was IGFBP-5 in amphioxus, whereas IGFBP-1, -2 and -3 apperaed in lamprey, IGFBP-4 in jawed fishes, and IGFBP-6 in teleost with a loss in birds. We also showed that the pregnancy-associated plasma protein A (PAPP-A) and PAPP-A2 metzincin proteases, which degrade several IGFBPs, might have appeared in non-vertebrates and that their two inhibitors, proMBP and STC, probably appeared before both proteases. Interestingly, the cleavage sites of IGFBP were restricted to some species : for IGFBP-2 and -5, it was present in mammals, birds and reptiles, but not in amphibians and fishes; for IGFBP-4 in Mammals only. Another important point is that another insulin-like peptide-binding protein found in the fruit fly, IMPL2, has probably disappeared in vertebrates. - Source: PubMed
Publication date: 2026/09/22
Fouchécourt SophieCallebaut IsabelleMonget Philippe - is a major human pathogen that can elicit immune-inflammatory responses and infections, largely driven by its broad repertoire of antigenic proteins. Understanding these factors is valuable for elucidating mechanisms of infection. - Source: PubMed
Publication date: 2026/09/02
Dalloul Rajaa S DSohail Muhammad UChennakkandathil SareenaSawarth HinaAl-Noubi MunaChoi SunkyuSchmidt Frank - Patients with chronic liver disease (CLD) frequently develop reduced bone mass and an increased risk of fragility fractures, making osteoporosis a major extrahepatic complication that affects long-term prognosis and quality of life. Although the association between CLD and osteoporosis is well recognized, epidemiological risk factors and the shared versus etiology-specific mechanisms remain incompletely integrated. Current clinical risk assessment relies largely on bone mineral density, which fails to capture microarchitectural deterioration and may underestimate true fracture risk. This review aimed to integrate current epidemiological and mechanistic evidence and examine emerging approaches to precision prevention and management of CLD-related osteoporosis. - Source: PubMed
Publication date: 2026/09/15
Wang WenjingLiu GuangyuYokus BurhanYan TaiqiangSun HaolinPacher PalWang Yan